MissionIRNewsBreaks — Cepton Technologies Inc. (NASDAQ: CPTN) Announces Participation in Upcoming RBC Capital Markets Global Industrials Conference

 Cepton Technologies (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, will be participating in the RBC Capital Markets Global Industrials Conference. The conference is scheduled for Sept. 13–14, 2022, in Las Vegas. Cepton’s chief financial officer Hull Xu will be hosting a breakout session during the two-day event; the session is slated to begin at 9:05 a.m. PT on Sept. 14. In addition, Cepton management will also be hosting investor meetings throughout the conference.

To view the full press release, visit https://ibn.fm/bAILp

About Cepton Technologies Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability while enabling scalable and intelligent 3D perception solutions across industries. Cepton has been awarded the largest-known ADAS lidar series production award in the industry to date, based on the number of vehicle models awarded, to support General Motors’ Ultra Cruise program. Cepton is also engaged with all other top-10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to the OEM and tier 1-studded Metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information about the company, visit www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Announces Record Revenue for Q2 2022

 Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company developing solutions to optimize and automate the supply chain process and providing its Fr8App platform for B2B cross-border shipping in the NAFTA region, today announced its revenue for the second quarter of 2022 for the period ended June 30, 2022. Among the highlights, Fr8Tech reported record quarterly revenue of $8.5 million for Q2 2022, up 60% from $5.3 million in Q1 2022 and up 45% from $5.9 million in Q2 2021. “Second quarter 2022 revenue, a record, increased 60% on a sequential quarter basis and 45% on a year-over-year basis,” said Fr8Tech CEO Javier Selgas. “The growth reflects greater traction in each of our dedicated capacity product, Fr8Fleet, and our U.S. domestic Fr8App services. While the distribution channel capacity scarcity improved and fuel price increases stabilized in the second quarter, we believe it is prudent to modify our full year guidance, and we continue to expect revenue to increase sequentially throughout the year.”

To view the full press release, visit https://ibn.fm/RzYBG

About Freight Technologies Inc.

Freight Technologies is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary Freight App Inc. (“Fr8App”) is a B2B cross-border shipping marketplace in the NAFTA region powered by AI and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions. The company is headquartered in Houston, Texas. For more information, please visit Fr8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program and Recent FDA Confirmation Position It for Favorable Valuation

 

• Lexaria is a global innovator of drug delivery platforms, including its patented DehydraTECH(TM) technology
• The company recently released information that would help its stakeholders research and understand how biotech and pharmaceutical companies are valued
• Based on some of the methodologies used in valuation, Lexaria is positioned favorably as its DehydraTECH-processed CBD for the treatment of hypertension has successfully reached the IND application stage, with the program recently receiving an additional boost
• The FDA agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, for its hypertension program

As a follow-up to recent coverage by Zacks Small-Cap Research, which valued the company at $15.00 (https://ibn.fm/moh25), global innovator Lexaria Bioscience (NASDAQ: LEXX) provided information to its stakeholders that would help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies.

“Valuation of equities is a complex task with innumerable risks and rewards that include far-reaching macro events as well as company-specific developments. It is nearly impossible to foresee all risks and rewards, but underlying logic-based evaluation is one way to provide a realistic framework of expectations that investors can use in their analysis,” the August 11 press release reads (https://ibn.fm/yrv8k).

One of the logic-based evaluations considers the stage at which a company’s drug development program has reached. According to the U.S. Food and Drug Administration (“FDA”), there are five steps to the drug development process: Discovery and Development, Preclinical Research, Clinical Research, FDA Drug Review, and, finally, FDA Post-Market Drug Safety Monitoring. However, not more than about 250 of 5,000-10,000 compounds tested during the Discovery stage successfully transition to the third step. Against this backdrop, Lexaria stands out, having completed the first two steps with its DehydraTECH-CBD for hypertension treatment, with favorable results to boot.

The company’s first advanced human clinical study (“HCS”) for hypertension, conducted in 2018, for example, showed that DehydraTECH drug delivery technology delivered 317% more CBD to the blood at 30 minutes. Later HCS’s evidenced rapid and sustained drop in blood pressure (HYPER-H21-1), up to a 23% average reduction in overnight blood pressure and reduced arterial stiffness (HYPER-H21-2), and a 41% overall reduction in pulmonary artery systolic pressure (“PASP”) in male subjects (HYPER-H21-3). Lexaria is set to announce results from its fourth HCS – HYPER-H21-4 – in Q4 2022 (https://ibn.fm/N5sjD).

If the HYPER-H21-4 study were registered with the FDA, Lexaria notes, it would possibly be a Phase 1B or 2A study. This information lends color to the company’s valuation going by a guide prepared by Bay Bridge Bio, which notes that a company’s valuation increases as its drug development progresses from Phase 1 through Phase 3. For example, at the start of a Phase I trial, a biotech company’s valuation would be $88 million, a figure that would then rise to $248 million at the start of Phase 2 study, finally eclipsing the $1 billion mark to settle at $1.119 billion when the Phase III trial begins. The figures increase further following an FDA approval of the drug candidate.

Considering the FDA’s recent confirmation that it agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, the company’s accelerated drug development program for hypertension therapeutics could wend way to a multi-billion-dollar valuation in due course. The pharmaceutical industry is rife with examples of such possibilities.

In March, for example, Pfizer Inc. (NYSE: PFE) completed the acquisition of clinical-stage company Arena Pharmaceuticals for a total consideration of $6.7 billion. At the time of the acquisition, Arena was expecting results for its Phase 3 trial undertaken to evaluate the safety and efficacy of the etrasimod drug candidate in patients with active ulcerative colitis (https://ibn.fm/uI4b5).

As a December 2021 report by accounting firm PwC notes, big pharma is set to spend anywhere between $5 billion and $15 billion and, in some cases, as much as $50 billion in 2022 to purchase promising biotech companies and their IP, as they seek to bring on board in new drugs that can become serious revenue generators (https://ibn.fm/zCx4o). Such acquisitions attest that biotech companies with little to no revenue can still be worth billions.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

 

• Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain’s connectivity patterns
• CYBN is leading the industry in developing proprietary psychedelic-based therapeutics
• The company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder

The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin (NEO: CYBN) (NYSE American: CYBN) is on the leading edge of this transformation, as the clinical-stage biopharmaceutical company focuses on progressing psychedelics to therapeutics by offering a new standard of care for mental-health disorders and improving patient outcomes.

Psilocybin is undergoing a transformation. Numerous studies have reported positive findings using psilocybin “for treating depression as well as smoking and alcohol addiction, and for reducing anxiety in the terminally ill,” reported Scientific America (https://ibn.fm/Wx1Cv). “Ongoing and planned studies are testing the drug for conditions that include opioid dependence, PTSD and anorexia nervosa. This scientific interest, plus growing social acceptance, is contributing to legal changes in cities across the U.S.”

The article provided a quick overview of the history of the substance, noting that “after a flurry of research in the 1950s and 1960s, psilocybin and all other psychedelics were abruptly banned, partly in response to their embrace by the counterculture. Following the 1971 United Nations Convention on Psychotropic Substances, psilocybin was classed in the U.S. as a Schedule I substance.

The article quoted David Nutt, a neuropsychopharmacologist at Imperial College London, as saying: “It’s the worst censorship of research in history.”

This “censorship” appears to be coming to an end as Nutt and others are leading a “research resurgence” focused on how psilocybin changes the brain’s connectivity patterns, including reducing connections within the usual networks while increasing links between less connected regions. “Just this year, a study showed that treatment involving psilocybin led to sustained network alterations, which seemed to correlate with reduced depression symptoms,” the article observed. “Two organizations are beginning final rounds of trials for psilocybin’s use for depression, which could lead to the substance’s first approval by the U.S. Food and Drug Administration.”

Cybin is heavily involved in this resurgence of research. The company is leading the industry in developing proprietary psychedelic-based therapeutics, with a pipeline featuring three psychedelic molecules —CYB003, CYB004 and CYB005 — that are derived from CYBN’s novel drug-discovery platform (https://ibn.fm/4ZfwT).

Cybin’s lead investigational molecule, CYB003, is a deuterated psilocybin analog derived from psilocybin, which is part of a family of molecules called indolamines that includes more common neurotransmitters, such as serotonin. The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect and potentially better tolerability for an overall better outcome for patients. CYB003 has the potential to effectively treat major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) and is currently being evaluated in a phase 1/2a clinical trial.

A deuterated dimethyltryptamine (“DMT”), CYB004 has been shown to exert its psychedelic effects by activating the 5-HT2A receptor. In its natural form, DMT is rapidly metabolized in the body, unstable and not orally bioavailable. However, preclinical studies indicate that the deuterated DMT can overcome these limitations and provide increased oral and pulmonary bioavailability, faster onset with lower doses, less patient variability, and better dose titration for fewer side effects and longer-acting desensitization of the serotonergic receptors. The company reports that CYB004, which is currently in a phase 1 in-human study, has the potential to effectively treat anxiety disorders.

The company’s third substance is CYB005, which is a discovery-phase phenethylamine derivative with the potential to effectively treat neuroinflammation and psychiatric conditions. CYB005 is in preclinical development.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Golden Matrix Group Inc. (NASDAQ: GMGI) Scores Big Q3 Win on International Expansion

 

• GMGI sets new bar for quarterly revenue, topping $9 million for first time
• The company currently has a string of 15 consecutive profitable quarters
• Golden Matrix is growing through international M&A activity and launching gaming products, including a new highly anticipated eSports platform

Tech stocks have rallied since the tech-laden Nasdaq hit a nearly two-year low in June. Most of the first half of the year was dominated by geopolitical drama, and international upheaval fueling recession concerns amid spiking inflation. None of that stopped Golden Matrix Group (NASDAQ: GMGI) from having its best revenue quarter ever, spearheaded by horizontal and vertical growth.

Golden Matrix, a provider of turnkey and white label gaming platforms and content, hasn’t filed its 10-Q quarterly report with the Securities and Exchange Commission yet, but did provide some color to investors on its third quarter of fiscal 2022, which ran from May-July. The Las Vegas-based company logged record revenues exceeding $9 million in the quarter, an improvement of approximately 177% from $3.25 million in the comparable quarter of fiscal 2021.

Meaningful progress in both its flagship business-to-business (“B2B”) division and new business-to-consumer (“B2C”) division undergirded the jump in revenue. GMGI CEO Brian Goodman called the record quarter “even more impressive when considering the impact of global economic headwinds and an unfavorable exchange rate throughout the quarter.”

The strength of the U.S. dollar is important to Golden Matrix as the bulk of its customers are overseas, particularly Asia-Pacific as far as B2B clients. Golden Matrix has chosen not to foray into the byzantine U.S. market, with its software designed to decline requests coming from within the country to maintain strict compliance with U.S. law. At the end of the quarter, GMGI had about 635 operators and approximately 6.5 million registered users across all its traditional B2B gaming platforms.

Internationally, GMGI’s GM-X System is the industry standard as a configurable and scalable gaming platform providing access to over 10,000 games from dozens of providers along with sophisticated analytics, retention tools, loyalty features, and more. Through GM-X, Golden Matrix offers an array of games, including slots, table games, live games, and sports. The company is also planning on expanding into the burgeoning eSports that is growing at a stunning 22% compound annual growth rate on its way to an estimated $12.5 billion by 2030. The new GMGI B2B eSports platform is expected to make its debut any time now.

Record quarterly revenue has also been spurred on by Golden Matrix taking an 80 percent stake in RKings, the United Kingdom-based owner of a popular skill tournament platform operated in the U.K. and Ireland. RKings gives players an opportunity to win a bevy of products from jewelry to golf clubs to exotic cars and vacations. In the latest quarter, RKings’ B2C competitions engaged more than 46,000 new registered users.

The company didn’t provide insight into EBITDA or net income in its recent news release, but investors surely will be looking forward to the regulatory filings to see if the string of profitable quarters – currently standing at 15 – continues.

For more information, visit the company’s website at www.GoldenMatrix.com. 

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – QSAM Biosciences Inc. (QSAM) Receives ‘Marketable Advantage’ Toward Manufacturing, Supply Chain of CycloSam(R)

 QSAM Biosciences (OTCQB: QSAM) recently received a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R), from the U.S. Patent & Trademark Office. “The patent protects how CycloSam is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in an efficient, facile and reproducible process at lower costs… The scope of this patent is fairly broad in that it not only protects the use of QSAM’s primary radioisotope, Samarium-153 (Sm-153), but also several other radioactive materials used in commercialized radiopharmaceuticals such as Lutetium-177 (Lu-177) and Yttrium-90 (Y-90) in conjunction with chelating agent DOTMP. This patent provides the potential to add additional radiopharmaceuticals to QSAM’s pipeline,” a recent article reads. “Preparation and delivery of radiopharmaceuticals have historically been a challenge, but we believe the protection we have received for our kit formulation and preparation can provide a marketable advantage for both the manufacturing and supply chain for CycloSam, as well as other drug candidates. We also believe CycloSam has potential to be a breakthrough therapy for both primary and secondary forms of bone cancer.”

To view the full article, visit https://ibn.fm/7XSt1

About QSAM Biosciences Inc.

QSAM Biosciences is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM’s initial technology, CycloSam(R) (Samarium-153 DOTMP), is a clinical-stage bone-targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed the FDA-approved Quadramet(R) (Samarium-153 EDTMP) radiopharmaceutical product, which is indicated for pain palliation. QSAM is led by an experienced executive team and board of directors that have completed numerous FDA approvals and multiple successful biotech exits. CycloSam has demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared human trial performed in 2020 at the Cleveland Clinic. This nuclear technology uses low specific activity Samarium-153 (resulting in far less long-lived europium impurities) and DOTMP, a chelator believed to reduce or eliminate off-target migration and targets sites of high bone turnover, making it, in management’s opinion, an ideal agent to treat primary and secondary bone cancers. Since CycloSam delivers targeted radiation selectively to the skeletal system and to bone tumors, it is also believed to be a great candidate for effectiveness trials in bone marrow ablation as preconditioning for bone marrow transplantation, as well as in procedures to reduce external beam radiation to bone tumors. This multi-patented drug candidate utilizes a radioisotope previously approved by the FDA combined with a novel chelant, DOTMP, that has demonstrated preliminary increased efficacy and decreased side effects in animal models and veterinary treatment of bone cancer in dogs. Further, CycloSam utilizes a streamlined, just-in-time manufacturing process that is already in place. Given these factors, management believes there is a strong pathway to commercialization for CycloSam. For more information, visit the company’s website at https://QSAMBio.com.

NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html